I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Sanofi ( SNY ) announced the acquisition of Dynavax ( DVAX ) for $15.50 per share, or $2. ...

Stocks stocks closed higher on Wednesday, as the Dow Industrials and S&P 500 registered record closing highs in a broad rally during a holiday-shortened session.The blue-chip Dow rose 288.75 points, or 0.60%, to 48,731.16. The S&P 500 gained 0.3% to end at 6,932.05 points, while the Nasdaq climbed 0.2%.Indexes have been climbing in recent days, buoyed in part by a rebound in AI-related names after last week’s selloff that was triggered by concerns about inflated valuations and high capital expenditures dent ...

Key Takeaways AMGN agreed to lower U.S. drug prices, align them with other developed markets and offer deep DTC discounts.AMGN expanded its AmgenNow program to Repatha, Aimovig and Amjevita with discounts of up to 80%.Amgen plans $2.5B in U.S. manufacturing and R&D investments tied to tariff exemptions.Amgen (AMGN) recently signed a landmark agreement with the Trump administration to lower drug prices in the United States.Through this deal, Amgen addresses the two major concerns that have plagued Big Pharma ...

Core Viewpoint - The Ademi Firm is investigating Dynavax for potential breaches of fiduciary duty and other legal violations related to its transaction with Sanofi, which involves a cash offer for shareholders [1][3]. Group 1: Transaction Details - Dynavax shareholders will receive $15.50 per share, valuing the company at approximately $2.2 billion [2]. - The transaction includes substantial benefits for Dynavax insiders as part of change of control arrangements [2]. Group 2: Investigation Focus - The transaction agreement imposes significant penalties on Dynavax for accepting competing bids, which may limit shareholder options [3]. - The investigation will assess whether the Dynavax board of directors is fulfilling their fiduciary duties to all shareholders [3].

Core Insights - Sanofi has entered into a definitive agreement to acquire Dynavax Technologies for $15.50 per share, totaling approximately $2.2 billion, which has led to a 40% increase in Dynavax's shares in pre-market trading [1][4] Group 1: Acquisition Benefits - The acquisition enhances Sanofi's adult immunization portfolio by adding Dynavax's hepatitis B vaccine, Heplisav-B, which features a two-dose regimen over one month, compared to the traditional three-dose schedule over six months [2][4] - Heplisav-B's faster dosing schedule is expected to improve vaccination compliance among adults and healthcare systems [2] - The deal also includes Dynavax's shingles vaccine candidate, Z-1018, currently in phase I/II development, expanding Sanofi's pipeline in a growing market due to aging populations [3][4] Group 2: Market Opportunity - In the U.S., nearly 100 million adults born before 1991 are unvaccinated against hepatitis B, indicating a significant public health need and market opportunity for Sanofi [6] - Shingles affects approximately one in three adults, leading to complications that create sustained demand for effective adult vaccines, further enhancing commercial prospects for Sanofi [6] Group 3: Strategic Advantages for Dynavax - The acquisition positions Dynavax's vaccine portfolio within a global pharmaceutical leader, leveraging Sanofi's infrastructure and expertise to maximize commercial reach [7] - Sanofi's capabilities are expected to advance the shingles program and other pipeline assets more efficiently through later-stage development [7] - The transaction provides immediate cash value to Dynavax's shareholders and mitigates execution and funding risks [7] Group 4: Transaction Details - The deal is expected to close in the first quarter of 2026, subject to customary closing conditions, with Sanofi funding the transaction using available cash resources [8]

The Dow Jones Industrial Average was up 0.1% as of 9:45 a.m. Eastern. The S&P 500 index was up less than 0.1% and the Nasdaq Composite was down 0.1%. Markets will close at 1 p.m. ET for Christmas Eve and are closed for Christmas. Markets will reopen for a full day of trading on Friday, however volumes are expected to be light this week with the holiday and most investors having closed out their positions for the year. Much of the focus remains on the state of the U.S. economy and where the Federal Reserve w ...

德纳维制药(DVAX.US)暴涨超39%，最高触及15.49美元，创2022年8月以来新高。消息面上，赛诺菲宣 布，同意以每股15.5美元的现金收购德纳维制药，旨在扩充其目前以流感疫苗业务为核心的疫苗产品 线。该报价较达德纳维制药周二的收盘价溢价39%，交易价值约22亿美元。此项收购有望于2026年第一 季度完成。(格隆汇) ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

通过此次收购，这家法国制药巨头将获得一款已在美国上市的乙肝疫苗，以及一款正处于早期人体试验 阶段的实验性带状疱疹疫苗。赛诺菲表示，此举将强化其在成人疫苗接种领域的市场布局。目前，赛诺 菲的疫苗产品组合已覆盖流感、呼吸道合胞病毒、脑膜炎、百日咳等多个适应症。 周三，德纳维制药(DVAX.US)盘前暴涨近40%，报15.56美元。消息面上，赛诺菲(SNY.US)同意以约22 亿美元的价格收购德纳维制药，旨在扩充其目前以流感疫苗业务为核心的疫苗产品线。根据赛诺菲周三 发布的声明，其将以每股15.50美元的现金价格，收购总部位于美国加利福尼亚州埃默里维尔市的德纳 维制药。这一报价较达德纳维制药周二的收盘价溢价39%。 ...

通过此次收购，这家法国制药巨头将获得一款已在美国上市的乙肝疫苗，以及一款正处于早期人体试验 阶段的实验性带状疱疹疫苗。赛诺菲表示，此举将强化其在成人疫苗接种领域的市场布局。目前，赛诺 菲的疫苗产品组合已覆盖流感、呼吸道合胞病毒、脑膜炎、百日咳等多个适应症。 智通财经APP获悉，周三，德纳维制药(DVAX.US)盘前暴涨近40%，报15.56美元。消息面上，赛诺菲 (SNY.US)同意以约22亿美元的价格收购德纳维制药，旨在扩充其目前以流感疫苗业务为核心的疫苗产 品线。根据赛诺菲周三发布的声明，其将以每股15.50美元的现金价格，收购总部位于美国加利福尼亚 州埃默里维尔市的德纳维制药。这一报价较达德纳维制药周二的收盘价溢价39%。 ...